Home LiteratureArticle Details

PMID: 24501315 Published · ppublish English

PIK3CA mutation predicts resistance to breast cancer therapy.

Cancer discovery ·Vol. 4 ·No. 2 ·2014-09-30

Abstract

Women with HER2-postive, hormone receptor-positive breast cancer and one or more mutations in PIK3CA were less likely to benefit from neoadjuvant chemotherapy and HER2-targeted therapies than those without a mutation, according to study results presented on December 12 at the 2013 San Antonio Breast Cancer Symposium in Texas.

Article Info

Journal

Cancer discovery

Abbr.

Cancer Discov

ISSN

DOI

10.1158/2159-8290.CD-NB2013-180

Published

2014-09-30

Indexed

2014-02-06

Updated

2014-11-20

Language

English

Country/Region

United States

NLM ID

101561693

External Links

PubMed source DOI: 10.1158/2159-8290.CD-NB2013-180 View journal details

Analysis Services

Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.

Business Email

E-mail: product@genelibs.com